Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00140959
First received: August 31, 2005
Last updated: May 24, 2013
Last verified: May 2013
  Purpose

A study to evaluate the effects of combination losartan versus combination atenolol in patients with ambulatory systolic hypertension.


Condition Intervention Phase
Hypertension
Drug: MK0954, losartan potassium/Duration of Treatment: 18 weeks
Drug: Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension.

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Mean daytime ambulatory systolic blood pressure

Secondary Outcome Measures:
  • Ambulatory BP
  • Pulse pressure
  • Trough sitting BP
  • Percentage of patients who reach goal ambulatory systolic BP

Estimated Enrollment: 120
Study Start Date: February 2003
Primary Completion Date: June 2004 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males or females at least 18 years of age who have ambulatory systolic hypertension.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00140959

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Publications:
Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
ClinicalTrials.gov Identifier: NCT00140959     History of Changes
Other Study ID Numbers: 2005_061, MK0954-309
Study First Received: August 31, 2005
Last Updated: May 24, 2013
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Atenolol
Hydrochlorothiazide
Amlodipine
Losartan
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Arrhythmia Agents
Sympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Diuretics
Natriuretic Agents
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Calcium Channel Blockers
Vasodilator Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists

ClinicalTrials.gov processed this record on April 17, 2014